Hyponatremia in Oncology Patients.

2区医学 Q2 Medicine

Frontiers of Hormone Research Pub Date : 2019-01-01 Epub Date: 2019-01-15 DOI:10.1159/000493245

Christian Grohé

引用次数: 6

Abstract

Hyponatremia is frequent in cancer patients and potentially deleterious. Cancer patients have specific requirements due to the nature and treatment of their disease, which can directly impact the occurrence and severity of hyponatremia, and limit treatment choices. Although essential for successful hyponatremia management, appropriate diagnostic testing is not routinely performed in the current practice. Despite clear evidence that hyponatremia is associated with poor outcome in oncology patients, most patients are still hyponatremic while under observation. Guidance on specific treatment of cancer patients with hyponatremia is needed to optimize patient care in the face of these challenges.

查看原文本刊更多论文

肿瘤患者的低钠血症。

低钠血症在癌症患者中很常见，并且具有潜在的危害性。癌症患者由于其疾病的性质和治疗有特定的要求，这可以直接影响低钠血症的发生和严重程度，并限制治疗选择。虽然对成功的低钠血症管理至关重要，但在目前的实践中，适当的诊断测试并没有常规进行。尽管有明确的证据表明低钠血症与肿瘤患者预后不良相关，但大多数患者在观察期间仍存在低钠血症。面对这些挑战，需要针对低钠血症癌症患者的具体治疗提供指导，以优化患者护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers of Hormone Research 医学-内分泌学与代谢

自引率

0.00%

发文量

期刊介绍： A series of integrated overviews on cutting-edge topics New sophisticated technologies and methodological approaches in diagnostics and therapeutics have led to significant improvements in identifying and characterizing an increasing number of medical conditions, which is particularly true for all aspects of endocrine and metabolic dysfunctions. Novel insights in endocrine physiology and pathophysiology allow for new perspectives in clinical management and thus lead to the development of molecular, personalized treatments. In view of this, the active interplay between basic scientists and clinicians has become fundamental, both to provide patients with the most appropriate care and to advance future research.